39 / 49
*Fisher’s exact test
DoR = duration of response: ORR: Objective response rate; DCR: Disease control rate
Seto, et al. Lancet Oncol 2014
JO25567: tumour response
Response, %
Bevacizumab + erlotinib
(n=75)
Erlotinib
(n=77)
p-value*
Complete response
4
1
–
Partial response
65
62
–
Stable disease
29
25
–
Progressive disease
0
8
–
Not evaluated
1
4
–
ORR
69
64
0.4951
DCR
99
88
0.0177
Median DoR: 13.3 months with bevacizumab + erlotinib
versus 9.3 months with erlotinib